Chargement en cours...
A Review of the Use of Biological Agents in Human Immunodeficiency Virus Positive Patients With Rheumatological Diseases
After approval, initial biologics etanercept, infliximab, and adalimumab became useful in the therapeutic armamentarium to treat rheumatoid arthritis (RA) patients who had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). However, all phase-III clinical trials submitted to t...
Enregistré dans:
| Publié dans: | Cureus |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Cureus
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7667623/ https://ncbi.nlm.nih.gov/pubmed/33209528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10970 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|